dabogratinib

all catalysts(0)

nothing on the calendar yet

News(3)

• Tyra shares slip as bladder cancer responses fall short of investor expectations
  Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
  biospace · 18d ago
• Tyra disappoints investors with bladder cancer data
  Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
  biopharma_dive · 19d ago
• Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
  Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premar…
  fiercebiotech · 20d ago